ContractWarrant Agreement • October 24th, 2018 • Harpoon Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT’), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS IN ACCORDANCE WITH APPLICABLE REGISTRATION REQUIREMENTS OR AN EXEMPTION THEREFROM. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE ISSUER THAT SUCH OFFER, SALE, TRANSFER, PLEDGE OR HYPOTHECATION OTHERWISE COMPLIES WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS. THIS WARRANT MUST BE SURRENDERED TO THE COMPANY OR ITS TRANSFER AGENT AS A CONDITION PRECEDENT TO THE SALE, TRANSFER, PLEDGE OR HYPOTHECATION OF ANY INTEREST IN ANY OF THE SECURITIES REPRESENTED HEREBY.
SUMMARY OF BASIC LEASE INFORMATIONLease • October 24th, 2018 • Harpoon Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Summary of Basic Lease Information (“Summary”) is hereby incorporated into and made a part of the attached Lease. Each reference in the Lease to any term of this Summary shall have the meaning as set forth in this Summary for such term. In the event of a conflict between the terms of this Summary and the Lease, the terms of the Lease shall prevail. Any capitalized terms used herein and not otherwise defined herein shall have the meaning as set forth in the Lease.
HARPOON THERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • October 24th, 2018 • Harpoon Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 24th day of May, 2017, by and among HARPOON THERAPEUTICS, INC., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor” and any additional Investor that becomes a party to this Agreement in accordance with Section 6.9 hereof.
FIRST AMENDED AND RESTATED ASSIGNMENT AND LICENSE AGREEMENTAssignment and License Agreement • October 24th, 2018 • Harpoon Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
This First Amended and Restated Assignment and License Agreement (this “Agreement”) is entered into as of October 19, 2018 (the “Amendment Date”), by and between Werewolf Therapeutics, Inc., a Delaware corporation, with a place of business c/o MPM Capital, 601 Gateway Boulevard, Suite 350, South San Francisco, CA 94080 (“Werewolf”), and Harpoon Therapeutics, Inc., a Delaware corporation with a place of business at 4000 Shoreline Court, Suite 250, South San Francisco, CA 94080 (“Harpoon”).
DISCOVERY COLLABORATION AND LICENSE AGREEMENT between HARPOON THERAPEUTICS, INC. and ABBVIE BIOTECHNOLOGY LTD. Dated as of October 10, 2017Discovery Collaboration and License Agreement • October 24th, 2018 • Harpoon Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This Discovery Collaboration and License Agreement (the “Agreement”) is made and entered into effective as of October 10, 2017 (the “Effective Date”) by and between Harpoon Therapeutics, Inc., a Delaware corporation (“Licensor”), and AbbVie Biotechnology Ltd., a Bermuda corporation (“AbbVie”). Licensor and AbbVie are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
CONFIDENTIAL CONSULTING AGREEMENTConsulting Agreement • October 24th, 2018 • Harpoon Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
This Consulting Agreement (“Agreement”) is entered into and made effective by and between Harpoon Therapeutics, Inc., having its address at Suite 250, 4000 Shoreline Ct., South San Francisco, CA 94005 (“Company”), and William E Picht, Jr having an address at (“Consultant”). In consideration of the mutual promises and covenants contained herein, and intending to be legally bound, Company and Consultant agree as follows:
December 10, 2016 VIA EMAIL AND U.S. MAIL Gerald McMahon, PhD Dear Jerry,Employment Agreement • October 24th, 2018 • Harpoon Therapeutics, Inc. • Biological products, (no disgnostic substances)
On behalf of Harpoon Therapeutics, Inc. (“Harpoon” or the “Company”), I am pleased to set forth the terms of your employment with the Company, should you accept our offer letter (the “Agreement”):
